We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,300 Open access books available
116,000 International authors and editors
125M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
The Impact of Donor Type and Quality on Renal Transplant Outcomes

Hung Do Nguyen¹, Kenneth Yong¹,², Rebecca Croke¹ and Wai H Lim¹,²

¹Sir Charles Gairdner Hospital, Department of Renal Medicine, Western Australia
²University of Western Australia, Western Australia Australia

1. Introduction

Renal transplantation improves survival of patients with end-stage kidney disease (ESKD) (Wolfe, McCullough et al. 2009). In most countries, including the United States and Australia, there continues to be a growing disparity between the limited availability of deceased-donor kidneys compared to potential transplant candidates. In contrast, live-donor kidney transplantation has been steadily increasing over time. It has been well established that the type (live or deceased donor kidneys) and quality (donor age and presence of donor comorbidities) of donor kidneys have a significant impact on renal allograft outcomes. In this chapter, we will focus on both live-donor and deceased donor kidney transplantation and the impact of donor factors and types on graft and patient outcomes. With the continuing shortage of deceased donor kidneys coupled with a growing number of older transplant candidates, there has been a greater acceptance of using older donor kidneys, including increased utility of expanded criteria donor (ECD) and donation after cardiac death (DCD) kidneys. We will look at the impact of using ECD and DCD kidneys on graft and patient survival, and to identify modifiable factors that may improve transplant outcomes in recipients receiving ECD and DCD kidneys. Finally, we will discuss whether the implementation of utility-based allocation strategies for deceased donor kidneys is an appropriate way forward to provide a balance between utility and equity in the distribution of deceased donor kidneys.

2. Live-donor kidney transplantation

Since its introduction over 50 years ago, live-donor kidney transplantation is associated with better graft and patient outcomes compared with deceased donor kidney transplantation. The majority of live-related kidney transplantation is from siblings and parents, although spousal donation is becoming increasingly more common. There have been many live donor factors that have been identified which could affect transplant outcomes and this will be discussed in greater details in this chapter.

2.1 Trends in live donor transplantation

Live-donor renal transplantation has increased considerably over time, with some countries like the United States and Australia reporting an increase of at least 50% over the past
decade (Horvat, Shariff et al. 2009). Even in countries without a deceased donor renal transplant program such as the Middle East and Asia, live-donor renal transplantation continues to grow substantially (Ghods and Savaj 2006; Horvat, Shariff et al. 2009). It is currently estimated that live-donor renal transplantation accounts for over 40% of total renal transplant numbers worldwide. According to the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry report, the proportion of live-donor renal transplantation has increased from 31% in 1998 to 44% in 2008 (Figure 1) (Campbell, McDonald et al. 2009). Similar increases have been reported in other countries including Europe and the United States (De Meester 1998; Oosterlee and Rahmel 2008; Horvat, Shariff et al. 2009; US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2009; ERA-EDTA Registry 2010).

Within the United States, Europe and Australia, the increased rates of live-donor renal transplantation are directly attributable to growth of live-unrelated donor (LURD) kidney transplants (Oosterlee and Rahmel 2008; Campbell, McDonald et al. 2009; US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2009; ERA-EDTA Registry 2010). In Australia, the proportion of LURD has increased substantially from 31% of overall live-donor transplants in 2000 to 50% in 2008. The majority of live-related donor (LRD) kidney transplants are from parental or sibling donors, whereas spousal donation accounts for the majority of LURD transplants. Furthermore, the adoption of laparoscopic donor nephrectomy techniques coupled with low rates of short- and long-term complications of kidney donation has also contributed significantly to the expansion of live-donor transplantation (Bia, Ramos et al. 1995; Schweitzer, Wilson et al. 2000).

Finally, there is greater acceptance of older live-donors over the past decade despite donor age having been shown to affect renal transplant outcomes. In the United States, the proportion of older donors >50 years age has increased by almost 7% between 1999 and 2008, with similar proportional increase in other countries (US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2009).

![Fig. 1. Living donor transplants as proportion of total transplants.](www.intechopen.com)
The Impact of Donor Type and Quality on Renal Transplant Outcomes

2.2 Outcome of live compared to deceased-donor kidney transplantation

Live-donor transplantation is associated with superior graft and patient outcomes compared with deceased-donor transplantation (Table 1) (Terasaki, Cecka et al. 1995; Gjertson and Cecka 2000; Campbell, McDonald et al. 2009; US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2009). In addition, the introduction of pre-emptive live-donor renal transplantation provides ESKD patients the option of avoiding dialysis (Mange, Joffe et al. 2001; Meier-Kriesche and Kaplan 2002; Liem and Weimar 2009). Finally, it has been established by several large single centre and registry studies that the superior outcomes of live-donor transplantation occur independently of human leukocyte antigen (HLA)-matching and donor or recipient characteristics (Terasaki, Cecka et al. 1995; Gjertson and Cecka 2000; Fuggle, Allen et al. 2010).

Large registry analyses from the United States, Europe and Australia have demonstrated a significant graft and/or patient survival advantage and possibly reduction in rejection risk in pre-emptive live-donor transplants compared to non-pre-emptive live-donor transplants, possibly related to avoidance of dialysis exposure (Donelly, Oman et al. 1995; Mange, Joffe et al. 2001; Milton, Russ et al. 2008). However, one study suggested that short duration of dialysis of <90 days prior to transplant had comparable graft survival to pre-emptive transplant recipients (Milton, Russ et al. 2008). Interestingly, unlike pre-emptive live-donor transplantation, pre-emptive deceased donor transplantation does not appear to be associated with improved graft or patient survival compared to non-pre-emptive deceased donor transplantation (Kessler, Ladriere et al. 2011).

![Table 1](https://www.intechopen.com)

<table>
<thead>
<tr>
<th></th>
<th>1 year graft / patient survival</th>
<th>5 year graft / patient survival</th>
<th>10 year graft / patient survival</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Australia</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live</td>
<td>96.8% / 98.7%</td>
<td>87.5% / 94.1%</td>
<td>68.8% / 86.7%</td>
</tr>
<tr>
<td>Deceased</td>
<td>91.6% / 96.4%</td>
<td>80.8% / 89.0%</td>
<td>58.6% / 72.6%</td>
</tr>
<tr>
<td><strong>United States</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live</td>
<td>95.7% / 98.3%</td>
<td>80.4% / 90.2%</td>
<td>57.0% / 76.5%</td>
</tr>
<tr>
<td>Deceased</td>
<td>90.5% / 95.2%</td>
<td>67.3% / 80.7%</td>
<td>41.0% / 60.6%</td>
</tr>
</tbody>
</table>

Table 1. Unadjusted 1, 5 and 10-year graft and patient survival rates following primary living and deceased donor transplantation in Australia & United States in 2008 (Campbell, McDonald et al. 2009; US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2009).

2.3 Effect of donor characteristics on live-donor kidney transplant outcomes

2.3.1 Donor gender

A disproportionately greater number of female donors have been observed in live-donor programs in most countries, including the United States and Australia (Kayler, Meier-Kriesche et al. 2002; Campbell, McDonald et al. 2009). In Australia, female donors accounted for 53% and 62% of overall LRD and LURD donors respectively, the latter likely to reflect the growth in spousal donation (Campbell, McDonald et al. 2009). The reason for the greater proportion of female donors remains unclear although differences
in medical (higher rates of cardiovascular disease in men) and psychosocial (financial issues and differing perception towards donation between genders) factors may be contributing (Bloembergen, Port et al. 1996; Schaubel, Stewart et al. 2000; Zimmerman, Donnelly et al. 2000).

In deceased donor kidney transplants, female donors have been shown to be associated with higher rates of rejection, poorer post-transplant graft function and possibly reduced graft and patient survival (Vereerstraeten, Wissing et al. 1999; Zeier, Dohler et al. 2002). In live-donor kidney transplantation, large single centre studies have suggested that female donors are associated with a greater risk of rejection and poorer post-transplant graft function (Oien, Reisaeter et al. 2005; Oien, Reisaeter et al. 2007), but this association has not been observed in large registry analyses (Kayler, Rasmussen et al. 2003; Lim, Chang et al. 2007). The failure to account for differences in donor-recipient body mass in these studies may in part explain the conflicting results between studies. It is plausible that the inverse association between female donors and post-transplant graft function may be attributed to ‘inadequate’ nephron mass from smaller female donors into larger male recipients with subsequent hyperfiltration injury and decline in renal function (Brenner, Cohen et al. 1992; Brenner, Lawler et al. 1996). Supporting this explanation, Poggio et al demonstrated that donors with larger kidney volume (typically donors with larger body sizes and male donors), as determined by 3D helical computed tomography scanning, were associated with lower rejection risk and improved post-transplant radionuclide glomerular filtration rate (GFR) (Poggio, Hila et al. 2006). However, selective transplantation of donor and recipient pairs based on size-matching remains debatable.

2.3.2 Donor-recipient relationship

A number of large single centre studies and registry analyses including United Network of Organ Sharing (UNOS) and ANZDATA have demonstrated similar graft and patient outcomes between LRD and LURD transplants, even though LURD were more likely to be older donors and often have poorer HLA-matching (Figure 8)(Terasaki, Cecka et al. 1995; Gjertson and Cecka 2000; Humar, Durand et al. 2000; Lim, Chang et al. 2007). Early studies have indicated that husband-to-wife (Terasaki, Cecka et al. 1997; Rosenberg, Jones et al. 2004) and child-to-mother live-donor transplants were associated with an increased risk of rejection and graft failure (Cecka 1995; Mahanty, Cherikh et al. 2001), possibly related to prior exposure to donor HLA antigens during pregnancy (Miles, Schaubel et al. 2008; Fuggle, Allen et al. 2010). In a recent ANZDATA analysis of 1989 primary live-donor renal transplants between 1995 and 2004, Lim et al reported that the risk of graft and patient survival was similar between LRD and LURD transplants. In this study, parental donors were associated with an increased risk of acute rejection at 6 months (odds ratio [OR] 1.69, 95% confidence interval [CI] 1.13-2.53) and lower GFR at 1 and 3 years post-transplant, but this did not translate to inferior graft or patient survival (Lim, Chang et al. 2007). In contrast, husband-to-wife and child-to-mother transplants were not associated with poorer graft outcomes in this study. Analysis of the UNOS database suggested that in recipients with genetic-predisposed ESKD such as focal segmental glomerulosclerosis (FSGS), type I diabetes and polycystic kidney disease (PKD), LRD kidney transplants may be associated with poorer graft outcomes compared with LURD transplants but this association remains debatable (Futagawa, Waki et al. 2005).
2.3.3 Expanded-criteria live donors

As with deceased donors, certain live donor characteristics have been identified that may have a significant impact on renal allograft outcomes. The identification of these donor characteristics in the assessment of potential live donor-recipient pairing may help in the selection of the most appropriate live donor to achieve the best graft outcomes. A large retrospective chart review of 264 live donor-recipient pairs transplanted between 1997 and 2003 at Cleveland clinic demonstrated that older donor age $\geq$ 45 years (compared with <45 years), donor radionuclide GFR $\leq$110mL/min (compared with >110mL/min), donor systolic blood pressure $\geq$120mmHg (compared with <120mmHg) and donor cholesterol $\geq$200mg/dL (compared with <200mg/dL) were associated with a greater risk of acute rejection, delayed graft function (DGF), poorer post-transplant graft function and/or graft loss at 2 and 3 years post-transplantation in the adjusted model. What was interesting about this study were the additive negative effects of increasing number of donor factors on graft function. In this study, there was no association between donor uric acid, fasting glucose, gender or race and graft outcomes (Issa, Stephany et al. 2007). Other studies have demonstrated a similar strong independent relationship between live donor GFR and post-transplant graft function (Poggio, Hila et al. 2006).

The recent meta-analyses by Iordanous Y et al of living expanded criteria kidney donors demonstrated that older live donors were associated with poorer composite outcomes of graft and patient survival compared to younger donors (meta-analysis of 12 studies, 72% vs. 80%, unadjusted relative risk [RR] of survival 0.89, 95% CI 0.83-0.95). However, the association between donor age and survival appeared to diminished over time (1980 - RR 0.79, 95% CI 0.65-0.96 compared to 1990 - RR 0.91, 95% CI 0.85-0.99), possibly related to the use of more potent immunosuppression (Iordanous, Seymour et al. 2009). The relationship between donor hypertension or lipid level and graft outcomes in this study remains unclear. Studies examining the association between donor obesity and donor urinary abnormalities (i.e. presence of proteinuria and/or haematuria pre-donation) are lacking. When examining live donor-recipient age difference, Ferrari P et al demonstrated that live donor-recipient pairs with $\geq$30 years age difference had similar graft and patient outcomes as those with lesser donor-recipient age difference suggesting large discrepancy in donor-recipient age difference should not discourage the decision for transplantation (Ferrari, Lim et al. 2011).

It is important to acknowledge that these are retrospective studies and therefore do not clearly establish causality between live donor factors and renal graft outcomes. Nevertheless, identifying unfavorable live donor characteristics could complement the assessments of recipients in stratifying their post-transplant risk of graft dysfunction or failure.

3. ABO-incompatible and desensitization programs

The complexity of live- and deceased donor transplantation has evolved over the years such that many transplanting centres are performing ABO-incompatible transplants and desensitizing highly allo-sensitized transplant candidates to improve their transplant potential. Other innovative programs that have been established to enhance live-donor transplantation include the paired kidney exchange program (as a strategy to overcome incompatible transplants) and tumour-resected kidney transplant program whereby patients with small renal tumours are considered for kidney donation following radical nephrectomy and resection of renal tumour.
3.1 ABO-incompatible live-donor transplants

Alexandre et al first described transplantation across the blood group barrier in 1987, but there has since been a broad expansion of this program worldwide (Alexandre G 1987). With the greater availability of more potent immunosuppression coupled with the capability to measure isohemagglutinin antibodies, the outcomes of ABO-incompatible live-donor kidney transplantation are comparable to compatible live-donor kidney transplantation (Crew and Ratner 2010). However, there continues to be an early significant risk of antibody-mediated rejection (AMR). The concept of blood group incompatible transplantation involves the removal of isohemagglutinin antibodies (i.e. antibodies formed against blood group antigen A and/or B) to low levels using immunoabsorption technique (ABO antibody-specific) or plasmapheresis (not ABO antibody-specific) thereby avoiding hyperacute rejection following transplantation. Although splenectomy was once considered standard practice pre-blood group incompatible transplantation to prevent early AMR, the introduction of anti-CD20 antibody rituximab has largely eliminated the need for splenectomy achieving equivalent outcomes. However, the need for pre-transplant rituximab remains debatable (Tanabe, Ischida et al. 2009). Tanabe et al recently reported on the outcome of 800 ABO-incompatible kidney transplants in Japan performed since 1989. The reported 5-year graft and patient survival in this cohort was 79% and 90% respectively (Tanabe K 2007). Acute AMR occurred in up to 30% of transplant recipients resulting in early graft loss in 10% of recipients with refractory AMR (Crew R 2010). Although acute AMR may be treated successfully with further immunoabsorption or plasmapheresis, recipients who develop AMR have poorer graft survival (AMR and no AMR - graft survival of 84% and 100% at 3 years and 49% and 95% at 8 years) and a greater risk of developing transplant glomerulopathy, especially in recipients with concurrent pre-transplant donor specific antibodies (DSA) (Einecke, Sis et al. 2009; Toki, Ishida et al. 2009). Acute AMR is less common after 3 months post-transplant, presumably related to the development of accommodation, a phenomenon of persistent anti-donor antibody in the absence of allograft injury (Dehoux and Gianello 2009).

3.2 ABO-incompatible deceased donor transplants

In 1991, an Organ Procurement Transplant Network (OPTN)/UNOS variance has approved a voluntary national allocation of blood group A2 and A2B deceased donor kidneys into blood group B and O transplant candidates to improve their transplant potential, although this allocation practice had already been adopted into clinical practice by the Midwest Transplant Network since 1986 (Nelson, Shield et al. 2002). As a result of this practice, 31% more blood group B transplant candidates with low anti-A IgG titres received a transplant achieving comparable graft survival as those who had received blood group B kidneys using conventional immunosuppression (10 year graft survival was 72% and 69% respectively) (Bryan, Nelson et al. 2004; Bryan, Winklhofer et al. 2005). Recent analysis of the United States Renal Data System (USRDS) database between 1995 and 2006 demonstrated that blood group O and B recipients (n=238) who had received blood group A2 kidneys had significantly shorter waiting-time compared to blood group compatible transplants (n=149,880). Graft loss and patient survival were similar in blood group A2 to B or O recipients and blood group compatible recipients (Hurst, Sajjad et al. 2010). These favourable reports suggest that this strategy should be considered in allocation programs to enhance the transplant potential of appropriate blood group B and O transplant candidates with low anti-A titres.
3.3 Desensitization of highly-sensitized patients for live-donor transplantation

There is an increasing number of transplant candidates who are allo-sensitized to HLA as a result of previous exposure to HLA antigens, typically following blood transfusions, prior transplantation and pregnancy. The presence of high levels of class I and/or II DSA (i.e. anti-HLA antibodies with reactivity against the potential donor leading to positive complement-dependent cytotoxicity [CDC] cross-match) is associated with poorer graft outcomes, including the development of acute and chronic AMR, transplant glomerulopathy and late graft loss (Eng, Bennett et al. 2008; Gloor, Winters et al. 2010; Eng, Bennett et al. 2011; Mujtaba, Goggins et al. 2011). A study by LeFaucheur et al demonstrated that the presence of DSA significantly reduces graft survival rates compared to recipients without DSA (1 year graft survival – 81% and 94% respectively and 8 years graft survival 47% and 78% respectively) (LeFaucheur, Suberbielle-Boissel et al. 2008) (Table 2). In addition, recent study by Mujtaba M et al demonstrated that the 3-year graft survival in highly-sensitized patients with lower total DSA (i.e. total mean fluorescent intensity [MFI] of <9500) was 100% compared to 76% in those with higher total DSA (i.e. total MFI >9500; p = 0.022) (Mujtaba, Goggins et al. 2011).

Studies reporting the utilization of desensitization technique to allow transplantation in highly-sensitized transplant candidates have focused predominantly on live-donor transplantation, which allows early planning and implementation of treatment at a suitable time. With the greater understanding of HLA antigens and anti-HLA antibodies, innovative techniques have been established to allow live-door transplantation across a ‘positive CDC cross-match’ barrier. Combinations of rituximab, plasmapheresis and/or intravenous immunoglobulin (IVIg) have been used successfully to desensitize highly allo-sensitized transplant candidates, therefore allowing live-donor transplantation to occur safely (Jordan, Vo et al. 2003; Gloor and Stegall 2010). The typical desensitization regimens involve either a single high dose of IVIg or combination plasmapheresis with low dose IVIg, although the latter may be more effective in achieving a negative CDC cross-match (Gloor, DeGoey et al. 2003; Stegall, Gloor et al. 2006). The addition of rituximab remains debatable and unsubstantiated and splenectomy has largely been eliminated from most desensitization protocols (Locke, Zachary et al. 2007). Current literature indicates that transplantation could safely proceed if DSA intensity is lowered sufficiently to render a negative CDC cross-match and/or an IgG titre of ≤16 by isohemagglutination. Following successful transplantation, ongoing monitoring of DSA and early recognition of AMR is crucial to avoid early graft loss. On re-exposure to donor antigens against which the recipient is sensitized, memory B lymphocytes in their spleen, bone marrow and lymph nodes undergo an amnestic reaction leading to the development of antibody-producing cells, which can produce high levels of DSA within days or weeks suggesting positive cross-match kidney transplantation requires both pre- and post-transplantation interventions to continually suppress DSA levels. Despite advances in desensitization techniques, AMR and transplant glomerulopathy occur in over 30% and 45% respectively in live donor positive cross-match kidney transplantations (Gloor J 2010).

3.4 Desensitization of highly-sensitized patients on deceased donor wait-list

Desensitization of deceased donor transplant wait-list candidates with multiple anti-HLA antibodies to enhance their transplant potential remains debatable due to the uncertain availability of deceased donor kidneys and these patients may remain on the deceased donor transplant wait-list indefinitely (Table 2). Vo et al reported the successful transplantation of 6
highly sensitized patients who received deceased donor kidneys following desensitization with IVIg (2g/kg on days 0 and 30) and rituximab (1g on days 7 and 22) over a 4-week period. These patients were on the deceased donor wait-list for 144±89 months (range 60-324 months), but had waited only an additional 5±6 months for a transplant. These patients achieved excellent graft and patient outcomes despite having a greater risk of acute rejection (Vo, Lukovsky et al. 2008). The same group reported an additional 45 successful deceased donor transplants in highly sensitized patients using a similar but modified desensitization approach using one instead of two doses of rituximab. In this cohort, desensitized patients waited for an additional 4.2±4.5 months before receiving a deceased donor graft. Overall graft failure and death at 2 years were 80% and 91% respectively, but almost 30% of graft loss was directly attributed to AMR (Vo, Peng et al. 2010).

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>AMR incidence (%)</th>
<th>1-year DCGS (%)</th>
<th>2-year DCGS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lefaucheur et al (2008)</td>
<td>43</td>
<td>35</td>
<td>89</td>
</tr>
<tr>
<td>Thielke et al (2009)</td>
<td>51</td>
<td>32</td>
<td>93</td>
</tr>
<tr>
<td>Gloor et al (2010)</td>
<td>119</td>
<td>41</td>
<td>89</td>
</tr>
<tr>
<td>Haririan et al (2009)</td>
<td>41</td>
<td>12</td>
<td>90</td>
</tr>
<tr>
<td>Vo et al (2008)</td>
<td>16</td>
<td>30</td>
<td>94</td>
</tr>
<tr>
<td>Vo et al (2010)#</td>
<td>76</td>
<td>29</td>
<td>87</td>
</tr>
</tbody>
</table>

Table 2. Incidence of antibody mediated rejection (AMR) and death-censored graft survival (DCGS) following positive-crossmatch kidney transplantation. #Stratified by donor type – DCGS at 1 and 2 years for live donor (LD) 90% and 90%; for deceased donor (DD) 82% and 80%.

4. Innovative live-donor programs

4.1 Paired kidney exchange

Blood group or cross-match incompatibility between a potential donor-recipient pair is often a major barrier for kidney transplantation. Paired kidney exchange (PKE), which was first described in 1986 (Rapaport F 1986), circumvents the incompatibility by allowing a live-donor to direct the donated kidney to a different but compatible recipient, with the intent that another donor will donate to the first donor’s designated recipient (Delmonico 2004). Most PKE programs involves the use of computer-generated algorithms to create potential donor-recipient pairings using virtual databases containing patient characteristics along with blood group types and degree of sensitization (de Klerk, Keizer et al. 2005). There are several alternatives to the conventional 2-way or 3-way kidney paired donation types, such that an altruistic donor could create a domino paired donation (i.e. kidneys from altruistic
The Impact of Donor Type and Quality on Renal Transplant Outcomes

Donor set off a chain of simultaneous transplants terminating in a donation to a candidate on the deceased donor wait-list (Gentry, Montgomery et al. 2011). Although overcoming incompatibility remains the primary focus of PKE, donor and recipients pairs may participate in the exchange in the hope of finding a better HLA-matched kidney or younger kidney amongst other reasons. Match rates for incompatible pairs can be as high as 50% (de Klerk M 2006) and as a result can increase transplant activity even in small populations by almost 10% (Ferrari P 2009). Successful PKE programs have been established in the Netherlands, South Korea, United Kingdom, United States and more recently Australia.

4.2 Tumour-resected kidney transplant program

Transplantation of donor kidneys following ex-vivo resection of small kidney tumours is a novel source of donor kidneys that was first described in 1995 (Penn I 1995). Although these kidneys are clearly outside the standard criteria for donor kidneys coupled with the small but potential transmission of donor-derived malignancy into recipients, the success of such program in many countries is encouraging.

The largest reported case series of utilizing donor kidneys with small renal cancers comes from Australia. In this single-centre program, 43 patients were transplanted with kidneys removed from patients with <3cm incidentally detected renal cell cancer, majority of which were patients undergoing radical nephrectomy for presumed renal cell cancer. In this program, a vigorous informed consent was undertaken and only older transplant candidates >60 years of age or those with significant comorbidities were eligible to receive these kidneys (Nicol D 2008). In this program, patient survival at 1 and 5 years of recipients of tumour-resected kidney transplants was 92% and 88% respectively, compared to 98% and 74% patient survival for patients on the deceased donor wait-list (n=153) and 99% and 97% patient survival for recipients of LURD renal transplants (n=120; log rank score 10.4, P = 0.005) (Brook, Gibbons et al. 2010). There was one tumour recurrence occurring at 9 years post-transplantation, but it was unclear whether this was donor-derived. An additional 22 similar successful cases from United States and Japan were reported with no documented tumour recurrence (Buell J 2005; Mannami, Mannami et al. 2008).

5. Deceased donor kidney transplantation

There continues to be an enormous disparity between the availability of deceased-donor kidneys and potential recipients. This problem is further exacerbated by a greater acceptance of older ESKD patients for renal replacement therapy. In Australia, acceptance of ESKD patients aged 70-74 years for renal replacement therapy has increased from 390 per million population (pmp) in 2004, to 469 pmp in 2008 (McDonald, Excell et al. 2009). Furthermore, the proportion of potential transplant candidates aged >65 years on the deceased donor wait-list has increased by 21% between 2005 and 2008 (Chadban, McDonald et al. 2006; Campbell, McDonald et al. 2009). The Scientific Registry of Transplant Patients (SRTR) has recorded a similar increase of prevalent potential recipients aged ≥70 years on the deceased donor wait-list, rising from 114 in 1990 to 2544 in 2004 (Rao, Merion et al. 2007). There has been little increase in deceased donor rates worldwide. In Australia, deceased donor rates have remained low at 11 donors pmp in 2009 (10 pmp in 2005), compared to 34 pmp in Spain, 24 pmp in United States and 17 pmp in the United Kingdom (Excell, Hee et al. 2010; Fabre, Murphy et al. 2010). However, there has been an increase in
acceptance of older donor kidneys in Australia, with the number of deceased donors aged ≥55 years increasing 1.8-fold between 2001-03 to 2007-09 (Excell, Hee et al. 2010). Kidneys from older donors are associated with poorer graft outcomes including late graft loss, chronic allograft nephropathy and higher risk of cardiovascular mortality (Meier-Kriesche, Cibrik et al. 2002; Oppenheimer, Aljama et al. 2004); this is partially offset by the reduction in mortality associated with reduced wait-list time. In addition, female-to-male donation, major donor kidney weight/recipient weight inadequacy, cerebrovascular accidents (CVA) as the cause of donor death and the presence of donor comorbidities such as diabetes have an adverse impact on graft and/or patient survival (Feldman, Fazio et al. 1996; Giral, Nguyen et al. 2005; Ahmad, Cole et al. 2009; Shaheen, Shaheen et al. 2010). However, utilization of kidneys from deceased donors who had developed acute renal failure prior to organ procurement does not appear to have an unfavorable effect on graft outcome (Deroure, Kamar et al. 2010). A continuous kidney donor risk index has been developed using registry data to quantify expected graft survival for any given set of donor characteristics relative to a healthy 40-year old donor and may be useful as a decision-making tool at the time of the deceased donor kidney offer (Rao, Schaubel et al. 2009). However, the significance of such index in the different transplant eras or population groups remains unclear. In the remaining chapter, we will focus primarily on the use and outcomes of ECD and DCD donor kidneys, which have become important source of deceased donor kidneys over the last decade.

5.1 Expanded-criteria donor (ECD) kidneys (Table 3)

With the ongoing shortage of deceased donor kidneys coupled with the continued growth of potential transplant candidates, there has been an increase utilization of ECD kidneys. Compared with non-ECD kidneys, ECD kidneys are associated with poorer graft outcomes. Between 2005 and 2009 in Australia, there has been a 1.3-fold increase in the number of ECD kidneys (Excell, Hee et al. 2006; Excell, Hee et al. 2010).

In 2002, OPTN/UNOS Board of Directors established a definition of ECD kidneys, which was based on a retrospective review of 29,068 recipients from SRTR database (Port FK 2002). The term ECD kidneys was assigned based on a ≥70% greater risk of developing graft failure when compared to younger donor kidneys (aged between 10 and 39 years) and defined as any donor aged ≥60 years, or any donor aged 50-59 years, with two of the following three donor criteria: CVA death, terminal creatinine >133 μmol/L, or hypertension (Metzger, Delmonico et al. 2003). Although the concept of ECD focuses primarily on advanced donor age, other risk factors such as CVA, hypertension, diabetes and high serum creatinine were also taken into account (Cosio, Qiu et al. 1996; Ojo, Leichtman et al. 2000). Multiple studies have demonstrated that recipients of ECD kidneys have better survival compared to potential recipients on the waiting-list but long-term outcomes associated with ECD grafts remains unclear (Wolfe, Ashby et al. 1999; Ojo, Hanson et al. 2001).

Further modification of the definition of ECD kidneys has been proposed in an attempt to further improve the stratification and identification of donor kidneys with increased risk of early graft dysfunction or graft loss. In 2001, Nyberg et al devised the Deceased Donor Score (DDS), which incorporated several donor-derived factors that have been shown to independently affect graft outcomes (Nyberg SL 2001; Nyberg SL 2003). However, this score has not been adopted widely for clinical application.
In a retrospective study of 2845 French transplant recipients aged ≥60 years, ECD kidneys were associated with poorer graft survival compared to non-ECD kidneys (Savoye, Tamarelle et al. 2007). The difference in graft survival was 6.2% at 12 months and 14.2% at 5 years (adjusted relative risk [RR] of graft failure associated with ECD kidneys compared to non-ECD kidneys was 1.98, p<0.01). Nonetheless, survival of ECD recipients was superior to potential recipients remaining on the waiting list (adjusted RR of potential recipients on waiting-list compared to recipients of ECD and non-ECD kidneys were 2.32 and 3.78 respectively, p<0.0001). Similarly, analysis of the SRTR between 1990 and 2005 demonstrated that recipients aged ≥70 years receiving ECD or non-ECD deceased donor kidneys had a 56% lower mortality risk compared to wait-listed dialysis patients aged ≥70 years (RR 0.59; 95%CI 0.53, 0.65; p<0.0001), and this benefit persisted in elderly patients with diabetes and hypertension (Rao, Merion et al. 2007). As the unadjusted 1-year graft and death-censored graft survival (DCGS) of elderly transplant recipients were 81% and 90% respectively; and were 67% and 85% respectively at 3 years, this suggested that a considerable proportion of these recipients die with functioning grafts.

A retrospective analysis of ANZDATA of 4466 deceased donor transplants between 1991 and 2005 reported poorer outcomes in recipients of ECD kidneys, compared to non-ECD kidneys (Collins, Chang et al. 2009). Compared to non-ECD kidneys, ECD kidneys were associated with poorer graft function and a greater risk of DGF, acute rejection and death-censored graft failure (DCGF).

The observed reduction in graft survival in recipients of ECD kidneys is likely related to an increase in glomerulosclerosis with the associated reduction in functional nephron mass, which has been shown to correlate with an increased risk of DGF, graft loss and poorer graft function (Gaber, Moore et al. 1995). On average, the adjusted graft survival of ECD kidneys is 8% lower at 1 year and up to 20% lower at 3-5 years compared to non-ECD kidneys (Ojo AO 2001).

Although ECD kidneys are associated with poorer outcomes compared to non-ECD kidneys, the contribution of donor age, especially the upper acceptable age limit on graft outcomes amongst ECD grafts remains unclear. In a retrospective analysis of the UNOS/OPTN database, the impact of donor age on 9580 ECD kidneys were examined (Chavalitdhamrong, Gill et al. 2008). There was no association between donor age and acute rejection, although ECD kidneys from donors aged ≥70 years had poorer function at 12 months compared to grafts from younger ECD donors. In an adjusted model, ECD kidneys from donors aged ≥70 years were associated with an increased risk of graft failure and patient death compared to ECD kidneys from donors aged 50-69 years (hazard ratio [HR] 1.37 and 1.37 respectively, p<0.01). When stratified by recipient age, ECD kidneys from donors aged ≥70 years (compared to ECD 50-69 years) were associated with an increased risk of DCGF for recipients aged 41-60 years (HR 1.48, 95%CI 1.06, 2.06; p=0.02) but not for older recipients aged >60 years (HR 1.12, 95%CI 0.86, 1.46; p=0.40), suggesting that older ECD kidneys may have a smaller unfavourable impact in older recipients. In contrast, an Italian study demonstrated that 3-year graft and patient survival was similar in recipients receiving ECD kidneys from donors >75 years and <75 years (Collini, Kalmar et al. 2009). This inconsistent finding may be explained by the greater use of double kidneys (from donors >75 years) in the Italian study.

As ECD kidneys are more susceptible to peri-transplant insults, strategies to reduce cold ischemic time, improve donor kidney preservation (Burdick JP) and preventing or reducing reperfusion injury using agents such as superoxide dismutase (Land W) or platelet-
activating factor receptor antagonists (Grino JM) may be beneficial. However, these strategies have not translated to improvement in renal graft outcomes. Initial avoidance of calcineurin-inhibitors (CNI) in early post-transplant period has been suggested to reduce the risk of DGF in recipients of ECD kidneys but this approach has not been adopted widely. Although there is a lack of consensus amongst transplant physicians and surgeons regarding the allocation of ECD kidneys, most would advocate selective utilization of these kidneys for older recipients (particularly avoiding recipients <40 years) (Merion, Ashby et al. 2005; Schold and Meier-Kriesche 2006), for recipients with extended wait-time (Carter, Chan et al. 2005; Cecka, Cohen et al. 2006) or to consider dual graft transplantation into a single recipient to avoid unnecessary discard of older donor kidneys (Waiser, Schreiber et al. 2000; Tan, Alfrey et al. 2004).

<table>
<thead>
<tr>
<th>Donor/recipient groups</th>
<th>Graft outcome</th>
<th>Patient outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collins M et al 2009 ANZDATA (n=4466)</td>
<td>1/5y DCGS*</td>
<td>1/5y patient survival*</td>
</tr>
<tr>
<td>Non-ECD &lt;50y</td>
<td>94% / 88%</td>
<td>97% / 92%</td>
</tr>
<tr>
<td>Non-ECD 50-59y</td>
<td>91% / 84%</td>
<td>97% / 90%</td>
</tr>
<tr>
<td>ECD 50-59y</td>
<td>87% / 81%</td>
<td>97% / 89%</td>
</tr>
<tr>
<td>ECD ≥60y</td>
<td>87% / 71%</td>
<td>96% / 87%</td>
</tr>
<tr>
<td>Collini A et al 2009 Single centre (n=192)</td>
<td>1/3y graft survival</td>
<td>10y patient survival</td>
</tr>
<tr>
<td>ECD &gt;75y</td>
<td>73% / 64%</td>
<td>81% / 81%</td>
</tr>
<tr>
<td>ECD &lt;75y</td>
<td>82% / 71%</td>
<td>92% / 90%</td>
</tr>
<tr>
<td>Savoye E et al 2009 Single centre (n=2845)</td>
<td>1/5y graft survival*</td>
<td>1/5y patient survival</td>
</tr>
<tr>
<td>Expanded criteria 0^</td>
<td>93% / 83%</td>
<td>ECD – 97% / 67%</td>
</tr>
<tr>
<td>Expanded criteria 1^</td>
<td>87% / 74%</td>
<td>Non-ECD – 98% / 91%</td>
</tr>
<tr>
<td>Expanded criteria 2^</td>
<td>87% / 65%</td>
<td></td>
</tr>
<tr>
<td>Expanded criteria 3^</td>
<td>83% / 55%</td>
<td></td>
</tr>
<tr>
<td>Chavalitdhamrong D et al 2008; OPTN/UNOS database (n=9580)</td>
<td>3/5y graft survival*</td>
<td>3/5y patient survival*</td>
</tr>
<tr>
<td>ECD 50-69y</td>
<td>69% / 55%</td>
<td>82% / 71%</td>
</tr>
<tr>
<td>ECD ≥70y</td>
<td>62% / 44%</td>
<td>75% / 58%</td>
</tr>
</tbody>
</table>

Table 3. Effect of expanded criteria donor on renal transplant outcomes. *p<0.05; #analysis in patients aged ≥60 years, ^expanded criteria risk factors including donor aged ≥60 years, donor hypertension, donor diabetes, donor death from cerebrovascular accident.


5.2 Donation after cardiac death donor kidneys

Over the last decade, the number of brain-death donors has steadily declined, in part attributed to changes in neurosurgical practice (Jüttler, Schwab et al. 2007). However, the use of DCD donor kidneys has increased substantially. In Australia, the number of DCD donors has increased from 1 to 42 between 2000 and 2009 (Excell, Hee et al. 2010), whereas in the United Kingdom, the proportion of DCD of all deceased donors has increased by 29% between 2000 and 2009 (Transplant 2010). The prolonged warm ischaemic period that invariably accompanies DCD kidney transplants is likely to explain the greater incidence of
DGF (Locke, Segev et al. 2007). As a result, DCD kidneys are more likely to be allocated locally to minimize cold ischaemic time. Recent analysis of the UK transplant registry demonstrated that compared with brain-death donor kidney transplants, recipients of controlled DCD donor kidneys of Maastricht category 3 (defined as donors awaiting cardiac arrest following withdrawal of life-sustaining treatment in intensive care unit (Kootstra, Daemen et al. 1995)) was associated with a significantly greater risk of DGF but lower risk of acute rejection up to 3 months post-transplant (Figure 2). For primary but not repeat renal allograft recipients of DCD kidneys, overall 5-year graft survival was comparable to primary and repeat renal allograft recipients of brain-death donor kidneys in unadjusted and adjusted models. Repeat renal allograft recipients of DCD kidneys have a greater risk of primary non-function compared to primary renal allograft recipients of DCD kidneys. Increasing donor and recipient age, as well as prolonged cold ischaemic time but not the presence of DGF or HLA-matching were associated with poorer graft outcomes in primary renal allograft recipients of DCD kidneys (Summers, Johnson et al. 2010). With comparable transplant outcomes between brain-death and controlled DCD donor kidneys, DCD kidneys are considered an acceptable source of donor kidneys although particular attention in reducing cold ischaemic time and avoidance of large donor-recipient age differences and avoidance of allocating DCD kidneys to repeat renal allograft recipients may be appropriate.

Fig. 2. Kaplan-Meier survival estimates comparing brain-death and cardiac-death donor grafts, stratified by primary and repeat grafts (adapted from Summers et al 2010).

5.3 Utility-based allocation strategies to maximise overall functioning graft years
Allocating younger donor kidneys to older potential recipients has raised concerns amongst many transplant physicians and surgeons, as many older recipients will die with functioning grafts. If these younger kidneys were re-allocated from older to younger recipients, a proportion may have continued to function for a substantial period in younger recipients. As older recipients have reduced life expectancies, adopting an allocation strategy that better matches the life expectancy of the donor kidney with that of the recipient
may be more appropriate (Meier-Kriesche, Schold et al. 2005). Allocation strategies that have been examined included the concept of donor-recipient age-matching and the creation of a kidney allocation score (KAS) to improve the utility of deceased donor kidneys. These strategies will be discussed in this chapter.

5.3.1 Age-matching
Allocation of deceased donor kidneys according to donor-recipient age-matching avoids the allocation of younger donor kidneys to older recipients and older donor kidneys to younger recipients according to a single donor and recipient age cut-off value. The Eurotransplant Seniors Program (ESP) is an example of an age-matching allocation model that has been successfully implemented in the allocation of deceased donor kidneys.

5.3.1.1 Eurotransplant seniors program
The foundation of ESP, which was established in 1999, was to preferentially allocate older donor kidneys ≥65 years to ABO-compatible, unsensitized older recipients ≥65 years receiving a primary graft (Cecka, Cohen et al. 2006). The ESP was designed to match the functional potential of donor kidneys ≥65 years to the functional requirements of older recipients aged ≥65 years. Although a degree of age-matching already occurred prior to the development of ESP such that the very young donor kidneys were seldom allocated to older recipients, this may be explained by younger healthier potential recipients near the top of the list declining a suboptimal donor graft, and therefore retain their place on the waiting list until a younger donor kidney becomes available. Similar practice also occurs in countries such as the United States and Australia where age-matching is not part of the standard allocation process (Segev 2009; Lim, Chang et al. 2010).

In ESP, donor kidneys were distributed locally to reduce cold ischaemic time, in an attempt to reduce the risk of DGF. Consequently, this program has not only resulted in an improvement in transplant access in older recipients by reducing wait-list times, younger recipients had also benefited from this program with improved access to younger donor kidneys (Smits, Persijn et al. 2002). Compared to ‘old-to-any’ (i.e. recipients of any age receiving a donor kidney ≥65 years) and ‘any-to-old’ (i.e. recipients aged between 60-64 years receiving donor kidneys of any age) transplants (allocated via Eurotransplant Kidney Allocation System [ETKAS]), recipients of ESP had significantly lower risk of DGF; presumably related to the reduction in cold ischaemic time. However, ESP recipients had a greater risk of acute rejection, presumably related to a greater degree of HLA-mismatch(es), which was ignored in the allocation of ESP kidneys. One and 5-year DCGS in ESP recipients were similar to ‘old-to-any’ recipients (1 year – 83% and 81% respectively; 5 years – 67% for both groups) but were inferior compared to ‘any-to-old’ recipients (1 year 90% and 5 years 81%) (Table 4). When stratified by donor age, the 1 and 5-year graft survival in the ESP group was 75% and 47% compared to 74% and 53% for ‘any-to-old’ recipients (1 year 90% and 5 years 81%) (Table 4). When stratified by donor age, the 1 and 5-year graft survival in the ESP group was 75% and 47% compared to 74% and 53% for ‘any-to-old’ recipients (1 year 90% and 5 years 81%) (Table 4). When stratified by donor age, the 1 and 5-year graft survival in the ESP group was 75% and 47% compared to 74% and 53% for ‘any-to-old’ recipients (1 year 90% and 5 years 81%) (Table 4). When stratified by donor age, the 1 and 5-year graft survival in the ESP group was 75% and 47% compared to 74% and 53% for ‘any-to-old’ recipients (1 year 90% and 5 years 81%) (Table 4).
improvement in graft and patient outcomes. An important and often overlooked finding in this study is that younger recipients of older donor kidneys have poorer survival, similar to that of the ‘any-to-old’ recipients allocated through the ETKAS system (Table 4).

Eurotransplant Senior DR-compatible Program is a new future initiative of the ESP to preferentially allocate kidneys to recipients with 0 HLA-DR mismatches and therefore potentially reducing the risk of rejection (de Fijter 2009). The outcome of this approach will be prospectively evaluated in the coming years.

5.3.1.2 Simulated age-matching allocation of deceased donor kidneys

In Australia, utilization of older donors has steadily increased, with donors aged ≥55 years increasing from 134 to 241 between 2001-03 and 2007-09 (i.e. an increase of 16% of overall donors) (Excell, Hee et al. 2010). A recent ANZDATA registry study of 4616 renal transplant recipients has demonstrated that the adoption an age-matching allocation model would lead to substantial improvement in the number of functioning graft years and associated cost savings (Lim, Chang et al. 2010). In this study, recipients ≥55 years had more than a 2.5-fold increased risk of death with functioning graft compared to recipients <55 years (HR 2.84, 95%CI 1.97, 4.10 for 0-1 year; HR 2.78, 95%CI 2.19, 3.53 for 1-8 years and HR 4.44, 95%CI 3.10, 6.35 for >8 years; all p-values <0.01). However, the risk of early (<1 year) and late (>8 years) DCGF was similar in younger and older recipients. Compared with younger donor grafts, older donor grafts ≥60 years were associated with a significant increased risk of DCGF, death with functioning graft and poorer post-transplant graft function. The application of an age-matching allocation model to this cohort would result in an additional 262 mean functioning graft years, which equates to $11.8-21.7 million dialysis cost savings (cost per patient per year on dialysis $45,000-$83,000) (Cass, Chadban et al. 2006). Similarly, analysis of the SRTR database of 74,998 deceased donor transplants performed between 1990 and 2002 demonstrated that if older recipients aged 60-64 years received younger donor grafts aged 15-50 years, the application of age-matching allocation would have increased graft life by 27,500 years, with estimated cost savings in excess of 1 billion dollars (Meier-Kriesche, Schold et al. 2005). However, at an individual level, the absolute impact of age-matching appears less impressive. In the ANZDATA study by Lim et al, Younger recipients of younger donor kidneys would on average have an additional 3 functioning graft years compared to older recipients receiving younger donor kidneys (11.6 vs 8.7 mean graft years respectively) and the negative impact of older donor kidneys on functioning graft years appears to be greater for younger compared to older recipients (9.3 vs 7.1 mean graft years respectively) (Table 4).

Retrospective analysis of the OPTN database demonstrated that for every 1 year increase in donor age, the risk of graft failure (HR 1.01, p<0.001) and death with functioning graft (HR 1.004, p<0.001) was increased substantially (Moers, Kornmann et al. 2009). The negative impact of donor age on graft survival appears maximal between donors aged between 36 to 40 years (Keith, Demattos et al. 2004). In a simulated age-matching allocation system, the reallocation of older donor grafts ≥65 years from younger recipients <65 years (old-to-young) to older recipients ≥65 years (old-to-old) would result in an absolute reduction in 10-year graft survival by 8% (from 21% to 13%, p<0.001), whereas reallocation of donor kidneys <65 years from recipients ≥65 years (young-to-old) to younger recipients <65 years (young-to-young) would result in an improvement in 10-year graft survival by 7% (19% to 26%, p=0.40). Unlike the ANZDATA study, there was no net benefit of implementing an old-for-old allocation system with regards to overall functional graft years (Table 4).
In 2004, a subcommittee of the UNOS/OPTN recommended that the establishment of a Kidney Allocation Score (KAS) based on Life Years From Transplant (LYFT - measures transplant utility), combined with panel reactive antibody (PRA), Donor Profile Index (DPI - measures donor quality) and dialysis time (measures transplant equity) could potentially lead to an increase in the total number of life years gained from a restricted number of available deceased donor kidneys (Wolfe, McCullough et al. 2009; OPTN 2010). LYFT is defined as the additional years of life that a potential transplant recipient could expect to gain as a consequence of the transplant as compared to not receiving a transplant. LYFT is calculated from an equation generated by statistical modeling of historical data combining donor/recipient groups.

<table>
<thead>
<tr>
<th>Donor/recipient groups</th>
<th>Graft outcome</th>
<th>Patient outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frei U et al 2008 ESP/ETKAS(^{n=3539})</td>
<td>D/R ≥55 (ESP)</td>
<td>5y patient DCGS(^\ast) 67%</td>
</tr>
<tr>
<td></td>
<td>D ≥65 / R – any age</td>
<td>67%</td>
</tr>
<tr>
<td></td>
<td>D – any age / R 60-64</td>
<td>81%</td>
</tr>
<tr>
<td>Lim W et al 2010 ANZDATA(^{n=4616})</td>
<td>D &lt;60 / R &lt;55</td>
<td>Mean graft years</td>
</tr>
<tr>
<td></td>
<td>D &lt;60 / R ≥55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥60 / R &lt;55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥60 / R ≥55</td>
<td></td>
</tr>
<tr>
<td>Keith D et al 2004 OPTN Registry(^{n=50,322})</td>
<td>D 30-41 / R 0-40</td>
<td>10y patient survival</td>
</tr>
<tr>
<td></td>
<td>D 30-41 / R ≥55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥55 / R 0-40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥55 / R ≥55</td>
<td></td>
</tr>
<tr>
<td>Moers C et al 2009 OPTN Registry(^{n=99,860})</td>
<td>D &lt;65 / R &lt;65</td>
<td>10y graft survival</td>
</tr>
<tr>
<td></td>
<td>D &lt;65 / R ≥65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥65 / R &lt;65</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D ≥65 / R ≥65</td>
<td></td>
</tr>
<tr>
<td>Waiser et al 2000 Single centre(^{n=1269})</td>
<td>D ≤55 / R ≤55</td>
<td>8y graft survival(^\ast)</td>
</tr>
<tr>
<td></td>
<td>D ≤55 / R &gt;55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D &gt;55/ R ≤55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D &gt;55/ R &gt;55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D &gt;55/ R &gt;55</td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Effect of age-matching allocation on graft and patient outcomes. \(^{\ast}\)p<0.05; \(^{\wedge}\)Prospective data. Abbreviation: ESP – Eurotransplant Senior Program, ETKAS – Eurotransplant Kidney Allocation System, ANZDATA – Australia and New Zealand Dialysis and Transplant Registry, OPTN – Organ Procurement Transplant Network, D – donor, R – recipient, DCGS – death-censored graft survival, DFG – death with functioning graft, y – year(s), NR – not reported. Adapted from Lim et al (Nephrol Dial Transplant 2010).
the observed biological effects of patient and donor characteristics on survival. The equation created had a C-value of 0.75, that is the equation predicted the potential transplant recipients with the longer lifetime 75% of the time, although the equation may be inaccurate for the prediction of lifetimes for potential transplant candidates with characteristics that differ from the historical group. A C-value of 0.75 is comparable to the model for end-stage liver disease (MELD) with a C-value of 0.64, commonly used by many transplanting centres to prioritize patients for liver transplantation based on expected survival (Sharma, Schaubel et al. 2008). In addition, based on DPI, the kidneys with the longest survival potential will be allocated according to the combined score of LYFT (80% of total score) and dialysis time/PRA (20% of total score), whereas kidneys with lesser potential for long-term survival will be allocated according to dialysis time and PRA, such that better donor kidneys are allocated to younger potential recipients, who will have the longest expected LYFT. Older potential recipients, who will have a lower expected LYFT and potential recipients with the longest dialysis time will be less likely to receive better donor kidneys but may have an advantage in being allocated shorter-lived kidneys more rapidly (i.e. shorter waiting-time). If deceased donor kidney allocation was based on the KAS, there would a total expected increase in LYFT of 2642 years during a single year of allocation as compared with the current allocation system in the United States. A perception that organ allocation is occurring in an inequitable manner could potentially reduce organ donor rates. Nevertheless, the utilization of KAS may improve allocation based solely on age-matching, with other patient factors such as diabetes, which are known to adversely affect graft and patient survival, are taken into account in the calculation of LYFT (Machnicki, Pinsky et al. 2009).

5.3.3 Positives and negatives of implementing utility-based allocation models

It remains unclear whether the implementation of utility-based allocation models will achieve a better balance between utility and equity. While kidney transplantation is more cost effective than dialysis, it will take considerable time for the expected lower long-term cost to offset the high initial cost associated with transplantation. In older recipients who are more likely to die with a functioning graft, the expense of transplantation may not be acceptable, on an economic basis, especially with a high-quality donor kidney. Although adoption of an allocation model based on LYFT is likely to increase functioning graft years, this model is difficult to implement and may even be perceived as being discriminatory to potential ‘high-risk’ potential recipients (e.g. indigenous and highly sensitised potential recipients) who will have a higher predicted graft loss, resulting in a lower LYFT (Young and Gaston 2000; Young and Gaston 2005). The applicability of LYFT based on historical data to more recent eras and patient cohorts, where there may be differing clinical practices and use of novel immunosuppressive agents remains uncertain. In addition, the optimal weighting of DPI, dialysis time or other factors in the calculation of KAS remains undecided. Although not directly considered in the KAS and age-matching allocation models, KAS may indirectly take into consideration social equity and possibly quality of life, assuming that younger recipients receiving younger donor kidneys will have a longer lifespan and therefore greater contribution to society compared to older recipients (Laupacis, Keown et al. 1996). In contrast, age-matching allocation is simpler but chronological age is often a poor estimate of physiological age and therefore, allocation policy based solely on age-matching could potentially disadvantage a number of healthy older potential recipients.
6. Conclusion

With the continuing shortage of deceased donor organs coupled with the increased utilization of marginal live and deceased donors including ECD and DCD donor kidneys, there have been considerable interest in examining the outcomes of these grafts. Over the last decade, there has been an expansion of innovative transplant programs, including paired exchange and tumour-resected kidney transplant programs, which has helped to overcome incompatible transplants and increase donor kidney pool respectively. In this chapter, understanding the association between live and deceased donor characteristics and transplant outcomes will assist clinicians and potential recipients in the informed process of donor selection as well as the prediction of graft outcomes following transplantation.

7. References


The Impact of Donor Type and Quality on Renal Transplant Outcomes


www.intechopen.com


The Impact of Donor Type and Quality on Renal Transplant Outcomes


www.intechopen.com


Kidney transplantation is a complex field that incorporates several different specialties to manage the transplant patient. This book was created because of the importance of kidney transplantation. This volume focuses on the complexities of the transplant patient. In particular, there is a focus on the comorbidities and special considerations for a transplant patient and how they affect kidney transplant outcomes. Contributors to this book are from all over the world and are experts in their individual fields. They were all individually approached to add a chapter to this book and with their efforts this book was formed. Understanding the Complexities of Kidney Transplantation gives the reader an excellent foundation to build upon to truly understand kidney transplantation.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.